newsfilter
← Latest News
Business Wire·

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody Phase 1 ASCENT clinical program established